Oral adverse reactions associated with etoricoxib, a common pain medication

Edel, Jeremy; Vered, Marilena; Grinstein-Koren, Osnat; Porat, Dalit; Lukach, Ludmila; Pettesh, Jacob; Kelner, Alex; Ianculovici, Clariel; Kaplan, Ilana

doi:10.1016/j.adaj.2019.01.028

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Etoricoxib (5‐chloro‐2‐[6‐methylpiridine‐3‐yl]‐3‐[4‐methylsulphonylphenyl]‐pyridine) is a highly selective COX2 inhibitor with a good safety profile, and a variety of infrequent adverse skin reactions 4‐9 . In recent years, cases of etoricoxib‐induced FDE have been appearing in the literature, confirmed by positive patch tests in residual lesions with etoricoxib 10% pet.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Etoricoxib‐induced fixed drug eruption: Report of seven cases

et al. 2020

View full text Add to dashboard Cite

Background Fixed drug eruption (FDE) is a characteristic form of intraepidermal CD8+ T cell‐mediated drug reaction, with repeated appearance of isolated or multiple skin lesions in the same location after receiving the offending drug. Non‐steroidal anti‐inflammatory drugs (NSAID) are the most common cause. Selective inhibitors of inducible cyclooxygenase 2 (COX‐2) provoke a lesser degree of allergic or idiosyncratic adverse reactions than conventional NSAID, but they can cause skin reactions of variable severity. Objective Etoricoxib has been related to a variety of unusual skin reactions, including several reports of FDE. Methods We perfomed epicutaneous test to diagnose patients with suspected etoricoxib fixe drug rash due to clinical features and reproducibility on at least two occasions. Results We present seven new cases of etoricoxib‐induced fixed drug eruption, with a diagnosis based on clinical presentation. This diagnosis was confirmed by an etoricoxib‐positive lesional patch test in six cases and by a positive low‐dose oral challenge in the other one. Two patients showed negative patch tests with celecoxib (10% in pet.) on the residual lesions, and oral tolerance was confirmed in one. Conclusion To our knowledge, this is the largest series on FDE induced by etoricoxib reported to date.

show abstract

Section: Discussionmentioning

confidence: 99%

“…or in dimethyl sulfoxide, 4–7 or with a positive lymphoblastic transformation test. 7 Other infrequent mucocutaneous reactions induced by etoricoxib have also been described, ranging from exfoliative lesions limited to oral mucosa, 8 to severe, even fatal toxicodermia 9…”

Section: Discussionmentioning

confidence: 99%